返回列表

AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology</h2><h2>AbCellera获得了Trianni Mouse®技术的美国专利

The Trianni Mouse®, AbCellera’s technology for generating large databases of human antibodies for drug discovery programs, is granted United States patent

Trianni Mouse®是AbCellera公司的一项技术,用于为药物研发项目生成人类抗体的大型数据库,该技术已获得美国专利

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug discovery programs with biotech and pharma partners. The United States Patent and Trademark Office (USPTO) issued patent no. 10,881,084 titled "Transgenic Animals and Methods of Use" to Trianni, Inc. (Trianni), an AbCellera Company.

为下一代抗体发现提供集中操作系统的技术公司AbCellera今天宣布,该公司已扩大了其知识产权(IP)投资组合,包括其Trianni Mouse®技术。AbCellera利用转基因动物技术生产人类单克隆抗体,用于其与生物技术和制药公司合作的药物研发项目。美国专利和商标局(USPTO)颁发了专利号。10881084,标题为“转基因动物和使用方法”,Trianni, Inc. (Trianni),一个AbCellera公司。

"This patent is an important addition to our IP portfolio, providing protection to our proprietary technology in the U.S.," said Carl Hansen, Ph.D., CEO of AbCellera and Trianni. "By generating fully human antibodies in the first step of the discovery process, we’re able to increase the speed and efficiency of our partners’ programs to develop therapeutic antibodies."

AbCellera和Trianni的首席执行官Carl Hansen博士说:“这项专利是我们知识产权组合的重要补充,为我们在美国的专有技术提供了保护。”“通过在发现过程的第一步中生成完整的人类抗体,我们能够提高我们合作伙伴项目开发治疗性抗体的速度和效率。”

Trianni’s genetic engineering technology, which AbCellera acquired in November 2020, is an advanced transgenic platform for developing mice that produce human antibodies. The flagship Trianni Mouse® platform was designed to maximize immune responses, increase antibody diversity, and preserve natural maturation of fully human antibodies. It is also a core platform for quickly developing increasingly powerful transgenic mouse technologies for use in partner programs.

AbCellera于2020年11月收购了Trianni的基因工程技术,这是一种先进的转基因平台,用于开发能产生人类抗体的老鼠。Trianni Mouse®旗舰平台旨在最大限度地提高免疫应答,增加抗体多样性,并保持全人抗体的自然成熟。它也是一个核心平台,用于快速开发越来越强大的转基因老鼠技术,用于合作伙伴程序。

About AbCellera Biologics Inc.

关于AbCellera bioologics Inc.

  • 用户注册

    扫码注册或下载尊嘉金融App注册
  • 极速开户

    2分钟填写开户信息,即时开户成功
  • 0佣交易

    随时随地开启港美A股0佣金交易

1个账户、1笔资金
0佣金买卖港股、美股、A股